Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market cap of $114.2 billion. Gilead specializes in developing and delivering innovative therapies to treat life-threatening diseases, with a focus on areas such as virology, oncology, and inflammatory diseases. Shares of GILD have underperformed the broader market over the past year. The stock has gained 21.5% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 36.4%. In 2024, GILD is up 20.9% compared to SPX’s 25.2% rise on a YTD basis. Zooming in…